Professor & Director of Research University of Cambridge

Printed as of 4/19/2024

Disclosures

Personal Commercial (19)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
American College of Cardiology	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Amgen	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Amgen Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Daiichi Sankyo	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Esperion	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
European Atherosclerosis Society	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
European Society of Cardiology	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Ionis Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
KrKa Phamaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Merck & Co., Inc.	Research/Research Grants	Significant (>= \$5,000)	Other
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Mylan Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	Other
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Pfizer Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Regeneron	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Sanofi-Aventis	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
The Medicines Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 12/5/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 12/5/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 12/5/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.